Form D · Biotechnology
Apexian Pharmaceuticals, Inc.
Indianapolis, IN · CIK 0001560913
Offering snapshot reported Mar 25, 2019 · SEC filing
- Reported sold
- $150K Offering amount: $2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 18, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 25, 2019 | Initial | $150,000 | No comparison | 1 | SEC filing |
| Jul 11, 2018 | Initial | $2,800,000 | No comparison | 7 | SEC filing |
| Dec 5, 2016 | Initial | $1,262,635 | No comparison | 5 | SEC filing |
| Feb 16, 2016 | Initial | $750,000 | No comparison | 3 | SEC filing |
| Jun 24, 2015 | Initial | $275,000 | No comparison | 3 | SEC filing |
| Jun 20, 2013 | Amendment | $2,488,899 | $500,000vs Oct 29, 2012 | 7 | SEC filing |
| Oct 29, 2012 | Initial | $1,988,899 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-335557
Source: Form D, filed Mar 25, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Barnard | Director |
| David Broecher | Director |
| David Broecker | Director, Executive |
| Steve Carchedi | Director, Executive |
| Martin F. Haslanger | Director, Executive |
| Martin Haslanger, Ph D | Director |
| Mark R. Kelley | Director |
| Mark R. Kelley, Ph D | Director |
| Mark R. Kelly, Ph D | Director, Executive |
| Richard Messman, Md | Executive |
| Richard Messmann | Executive |
| Roger Miller | Executive |
| Homer Pearce | Director |
| Homer Pearce, Ph D | Director |
| Timothy Tichenor | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
20 N. Meridian Street Suite 801
Indianapolis, IN, 46204
Indianapolis, IN, 46204